• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Immunogenicity With Subcutaneous Infliximab: The Devil Is in the Details.

作者信息

Hanzel Jurij

机构信息

Department of Gastroenterology, University Medical Center Ljubljana, University of Ljubljana, Ljubljana, Slovenia.

出版信息

Clin Gastroenterol Hepatol. 2025 Jul 11. doi: 10.1016/j.cgh.2025.05.020.

DOI:10.1016/j.cgh.2025.05.020
PMID:40653286
Abstract
摘要

相似文献

1
Immunogenicity With Subcutaneous Infliximab: The Devil Is in the Details.皮下注射英夫利昔单抗的免疫原性：细节决定成败。
Clin Gastroenterol Hepatol. 2025 Jul 11. doi: 10.1016/j.cgh.2025.05.020.
2
Infliximab for maintenance of medically-induced remission in Crohn's disease.英夫利昔单抗维持克罗恩病的药物缓解
Cochrane Database Syst Rev. 2024 Feb 19;2(2):CD012609. doi: 10.1002/14651858.CD012609.pub2.
3
Meta-Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease.荟萃分析：炎症性肠病中静脉注射与皮下注射英夫利昔单抗的比较
Aliment Pharmacol Ther. 2025 Aug;62(4):380-388. doi: 10.1111/apt.70267. Epub 2025 Jul 10.
4
Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
Clin Gastroenterol Hepatol. 2025 May 14. doi: 10.1016/j.cgh.2025.03.021.
5
Impact of HLADQA1*05 and HLADQA1*03 on Safety and Loss of Response to Anti-Tumor Necrosis Factor in Patients With Inflammatory Bowel Disease.HLA-DQA1*05和HLA-DQA1*03对炎症性肠病患者使用抗肿瘤坏死因子治疗的安全性及反应丧失的影响
J Crohns Colitis. 2025 Jun 4;19(6). doi: 10.1093/ecco-jcc/jjae178.
6
Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review.
Inflamm Bowel Dis. 2009 Aug;15(8):1264-75. doi: 10.1002/ibd.20899.
7
Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.用于维持克罗恩病缓解的肿瘤坏死因子-α抗体。
Cochrane Database Syst Rev. 2008 Jan 23(1):CD006893. doi: 10.1002/14651858.CD006893.
8
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-α) inhibitors, adalimumab and infliximab, for Crohn's disease.TNF-α 抑制剂（阿达木单抗和英夫利昔单抗）治疗克罗恩病的系统评价和经济评估。
Health Technol Assess. 2011 Feb;15(6):1-244. doi: 10.3310/hta15060.
9
Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.生物制剂在慢性炎症性疾病中的免疫原性：一项系统综述。
BioDrugs. 2017 Aug;31(4):299-316. doi: 10.1007/s40259-017-0231-8.
10
Comparative Efficacy of Subcutaneous and Intravenous Infliximab and Vedolizumab for Maintenance Treatment of TNF-naive Adult Patients with Inflammatory Bowel Disease: A Systematic Literature Review and Network Meta-analysis.比较皮下注射和静脉注射英夫利昔单抗与维得利珠单抗治疗 TNF 初治成人炎症性肠病患者的维持治疗效果：系统文献回顾和网络荟萃分析。
Dig Dis Sci. 2024 May;69(5):1808-1825. doi: 10.1007/s10620-023-08252-1. Epub 2024 Mar 18.